# MOIO (NCT05078047)

> Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05078047
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: UNICANCER
- Conditions: Lung Cancer Metastatic; Renal Cell Carcinoma; Head and Neck Cancer; Triple Negative Breast Cancer; Merkel Cell Carcinoma; Hepatocellular Carcinoma; Melanoma; Urothelial Carcinoma; Colorectal Carcinoma With Microsatellite Instability; Esophageal Squamous Cell Carcinoma; Endometrial Carcinoma; Cervical Cancer; Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma; Basal Cell Carcinoma; Squamous Skin Carcinoma
- Interventions: Reduced dose intensity of IO
- Enrollment: 646
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on MOIO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 47
- Bluesky threads: 3
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=moio-nct05078047

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05078047", "email": "<work email>"}; the inbox owner confirms by the emailed link.